Personalis Inc (NASDAQ: PSNL) stock jumped 22.73% on Monday to $1.35 against a previous-day closing price of $1.10. With 3.07 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.35 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.5600 whereas the lowest price it dropped to was $1.1450. The 52-week range on PSNL shows that it touched its highest point at $4.31 and its lowest point at $0.89 during that stretch. It currently has a 1-year price target of $4.70. Beta for the stock currently stands at 1.64.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PSNL was up-trending over the past week, with a rise of 26.17%, but this was up by 42.47% over a month. Three-month performance dropped to -23.73% while six-month performance fell -35.71%. The stock lost -46.00% in the past year, while it has lost -31.82% so far this year. A look at the trailing 12-month EPS for PSNL yields -2.38 with Next year EPS estimates of -1.75. For the next quarter, that number is -0.50. This implies an EPS growth rate of 10.73% for this year and 20.87% for next year. EPS is expected to decline by -13.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -26.59%.
Float and Shares Shorts:
At present, 46.71 million PSNL shares are outstanding with a float of 39.30 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.74 million, which was 1.52% higher than short shares on Sep 28, 2023. In addition to Mr. Christopher M. Hall as the firm’s President, CEO & Director, Mr. Aaron L. Tachibana serves as its CFO & COO.
Through their ownership of 76.02% of PSNL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 31.75% of PSNL, in contrast to 27.64% held by mutual funds. Shares owned by individuals account for 18.70%. As the largest shareholder in PSNL with 11.79% of the stake, ARK Investment Management LLC holds 5,719,427 shares worth 5,719,427. A second-largest stockholder of PSNL, JPMorgan Investment Management, I, holds 2,288,976 shares, controlling over 4.72% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in PSNL, holding 2,053,485 shares or 4.23% stake. With a 12.46% stake in PSNL, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 6,046,006 shares are owned by the mutual fund manager. The JPMorgan Small Cap Growth Fund, which owns about 3.18% of PSNL stock, is the second-largest Mutual Fund holder. It holds 1,541,901 shares valued at 1.48 million. Vanguard Total Stock Market ETF holds 2.84% of the stake in PSNL, owning 1,375,373 shares worth 1.32 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PSNL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PSNL analysts setting a high price target of $7.50 and a low target of $2.30, the average target price over the next 12 months is $4.70. Based on these targets, PSNL could surge 455.56% to reach the target high and rise by 70.37% to reach the target low. Reaching the average price target will result in a growth of 248.15% from current levels.
Summary of Insider Activity:
Insiders traded PSNL stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 10,000 while 56,885 shares were sold.